Abstract 7P
Background
RNA modifications play an important role in gene expression and cellular functions. Regulatory genes for RNA modifications, such as methyltransferase 1, tRNA methylguanosine (METTL1) and adenosine deaminase RNA specific B1 (ADAR2), have been correlated with cancer progression due to their effects on mRNA and tRNA editing.
Methods
In this study, the association between polymorphisms in 25 RNA modification regulatory genes and the prognosis of 744 non-small cell lung cancer (NSCLC) patients was evaluated. Among the 21 single nucleotide polymorphisms (SNPs) studied, three were significantly associated with the overall survival (OS) of patients.
Results
The SNP rs10877013T>C in METTL1 gene was significantly associated with better OS (under a dominant model, adjusted hazard ratio [aHR] = 0.67, 95% confidence interval [CI] = 0.48-0.93, P = 0.02). METTL1 rs10877013 is located in intronic region, so rs703842G>A located in METTL13′untranslated region (3′UTR) with a strong LD (D′ = 1.0 and r2 ≥ 0.9) was found. The SNPs rs3788152A>C and rs414743G>A in the ADAR2 gene were associated with significantly worse OS (under a dominant model, aHR = 1.46, 95% CI = 1.05-2.03, P = 0.03; under a codominant model, aHR = 1.40, 95% CI = 1.02-1.93, P = 0.04, respectively). A dual luciferase assay showed a significantly higher promoter activity of METTL1 with the rs703842 A allele than with the G allele in H1299 (P = 6.5×10-6) and H1703 lung cancer cells (P = 0.03). Knockdown of METTL1 with specific siRNA induced cell apoptosis and decreased cell proliferation, invasion, and migration in lung cancer cells.
Conclusions
In conclusion, the investigation reveals that genetic variations METTL1 rs10877013T>C, ADAR2 rs3788152A>C, and ADAR2 rs414743G>A polymorphisms within RNA modification regulatory genes are associated with survival outcomes of NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
22P - Pre-clinical development of CVGBM: A therapeutic mRNA-based multiepitope vaccine for glioblastoma
Presenter: Ronja Mülfarth
Session: Poster session 07
23P - Germline testing in a selected cohort of non-small cell lung cancer (NSCLC) patients: Final results from the INHERITY LC study
Presenter: Maria Zurera Berjaga
Session: Poster session 07
24P - Assessment of an AI algorithm to classify germline variants in the ATM cancer predisposition gene
Presenter: Nooshin Bayat
Session: Poster session 07
25P - NGS-based identification of novel hereditary breast/ovarian cancer genes in patients with clinical features of genetic predisposition
Presenter: Ekaterina Kuligina
Session: Poster session 07
26P - Multi-feature cell free DNA analysis and ensemble machine learning for early detection of cancer
Presenter: Seongmun Jeong
Session: Poster session 07
27P - Molecular insights on cutaneous melanoma hyperpigmentation and therapy resistance
Presenter: Elena Andreucci
Session: Poster session 07
28P - Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy
Presenter: Szonja Kovács
Session: Poster session 07
29P - Considering intra-patient response variability in clinical trials: Implications for treatment efficacy and survival
Presenter: Caryn Geady
Session: Poster session 07
Resources:
Abstract
30P - CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors
Presenter: Yang Zheng
Session: Poster session 07
31P - Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors
Presenter: Li Lin
Session: Poster session 07